title: Robust in vivo differentiation of t(8;21)-positive acute myeloid leukemia blasts to neutrophilic granulocytes induced by treatment with dasatinib.
authors.forename: N
authors.initials: N
authors.lastname: Chevalier
authors.forename: M L
authors.initials: ML
authors.lastname: Solari
authors.forename: H
authors.initials: H
authors.lastname: Becker
authors.forename: M
authors.initials: M
authors.lastname: Pantic
authors.forename: F
authors.initials: F
authors.lastname: Gärtner
authors.forename: A
authors.initials: A
authors.lastname: Maul-Pavicic
authors.forename: J
authors.initials: J
authors.lastname: Hübner
authors.forename: R
authors.initials: R
authors.lastname: Wäsch
authors.forename: A
authors.initials: A
authors.lastname: Schmitt-Gräff
authors.forename: M
authors.initials: M
authors.lastname: Lübbert
mesh_terms: D001752:Blast Crisis / Q000188:drug therapy / Q000235:genetics / Q000473:pathology; D002454:Cell Differentiation / Q000187:drug effects*; D002891:Chromosomes, Human, Pair 21 / Q000235:genetics; D002898:Chromosomes, Human, Pair 8 / Q000235:genetics; D000069439:Dasatinib; D005434:Flow Cytometry; D006098:Granulocytes / Q000166:cytology* / Q000187:drug effects; D006801:Humans; D017404:In Situ Hybridization, Fluorescence; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D009504:Neutrophils / Q000166:cytology* / Q000187:drug effects; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D011743:Pyrimidines / Q000627:therapeutic use*; D015996:Survival Rate; D013844:Thiazoles / Q000627:therapeutic use*; D014178:Translocation, Genetic; D016896:Treatment Outcome
chemical_list: D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D013844:Thiazoles; D011505:Protein-Tyrosine Kinases; D000069439:Dasatinib